Status:
COMPLETED
A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea
Lead Sponsor:
Genzyme, a Sanofi Company
Conditions:
Clostridium Enterocolitis
Pseudomembranous Colitis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Approximately 520 patients will be entered into this study taking place throughout the US and Canada. This study aims to determine if an investigational drug is safe and effective for treating symptom...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- 18 years of age
- The presence of CDAD at the time of enrollment with no other likely etiology for the diarrhea
- Less than or equal to 48 hours of treatment with metronidazole, vancomycin or other antibacterial therapy specific for CDAD
- Baseline serum potassium \> 3.0 mmol (meq)/L
- Patient considered sufficiently stable clinically to likely complete a 6 week study period
Exclusion
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
End Date :
February 1 2007
Estimated Enrollment :
520 Patients enrolled
Trial Details
Trial ID
NCT00106509
Start Date
March 1 2005
End Date
February 1 2007
Last Update
March 5 2015
Active Locations (140)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States, 85006
2
Phoenix, Arizona, United States, 85012
3
Rogers, Arkansas, United States, 72756
4
Burbank, California, United States, 91505